Filing Flows › Sarepta Therapeutics (SRPT) › R&D spending
Sarepta Therapeutics (SRPT) R&D spending by quarter
Sarepta Therapeutics' R&D spending was $82.5M in Q3 2026 (third quarter 2026), -10% from Q2 2026. Over the last 5 quarters it ranged from $82.5M (Q3 2026) to $325M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $82.5M | -10% | -62% |
| Q2 2026 | $91.3M | -41% | — |
| Q1 2026 | $154M | -53% | — |
| Q4 2025 | $325M | +49% | — |
| Q3 2025 | $219M | — | — |
Q3 2026 at a glance
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Sarepta Therapeutics' R&D spending?
Sarepta Therapeutics' R&D spending was $82.5M in Q3 2026 (third quarter 2026), -10% from Q2 2026.
How has Sarepta Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $82.5M (Q3 2026) to $325M (Q4 2025).